The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small cell lung cancer in people whose disease has progressed following ...
The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small cell lung cancer in people whose disease has progressed following ...
(Reuters) -The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris. Amgen's drug will be marketed under ...
(This May 16 story has been officially corrected to change the pricing estimate in paragraph 4) (Reuters) - The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen ...
The Food and Drug Administration has approved a drug made by Amgen to treat the most deadly form of lung cancer. The drug, called Imdelltra, can be used for patients with advanced small-cell lung ...
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for severe chronic obstructive pulmonary disease ...